|
|
HL7 - Version 2.8.2 |
|
|
| Interpretation: | Bewertung des Ergebnisses / Meßwerts |
| OID Table: | 2.16.840.1.113883.12.78 |
| Codesystem OID: | 2.16.840.1.113883.5.83 Version 4 |
| Value Set OID: | 2.16.840.1.113883.1.11.78 |
| Binding: | universal |
| Expansion: | all codes from codesystem |
| Vocabulary Domain: | tbd |
| Table Type: | HL7 |
| Case insensitive: | Falsch |
| Steward: | OO |
| Section | 2.C.2.46 |
| Value | Description | German Interpretation | Comment | Chapter |
|---|---|---|---|---|
| L | Low | The result for a quantitative observation is below the lower limit of the reference range (as defined for the respective test procedure). Synonym: Below low normal |
2.C.2.46 | |
| H | High | The result for a quantitative observation is above the upper limit of the reference range (as defined for the respective test procedure). Synonym: Above high normal |
2.C.2.46 | |
| LU | Very low | Significantly low: A test result that is significantly lower than the reference (normal) or therapeutic interval, but has not reached the critically low value and might need special attention, as defined by the laboratory or the clinician. Note: This level is situated between ‘L’ and ‘LL’. | 2.C.2.46 | |
| HU | Very high | Significantly high: A test result that is significantly higher than the reference (normal) or therapeutic interval, but has not reached the critically high value and might need special attention, as defined by the laboratory or the clinician. Note: This level is situated between ‘H’ and ‘HH’. | 2.C.2.46 | |
| LL | Critically low | The result for a quantitative observation is below a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure). Synonym: Below lower panic limits |
2.C.2.46 | |
| HH | Critically high | The result for a quantitative observation is above a reference level at which immediate action should be considered for patient safety (as defined for the respective test procedure). Synonym: Above upper panic limits |
2.C.2.46 | |
| < | Off scale low | The result is below the minimum detection limit (the test procedure or equipment is the limiting factor). Synonyms: Below analytical limit, low off scale |
2.C.2.46 | |
| > | Off scale high | The result is above the maximum quantifiable limit (the test procedure or equipment is the limiting factor). Synonyms: Above analytical limit, high off scale |
2.C.2.46 | |
| N | Normal | The result or observation value is within the reference range or expected norm (as defined for the respective test procedure). Note: Applies to numeric or non-numeric results. |
2.C.2.46 | |
| A | Abnormal | anormal | The result or observation value is outside the reference range or expected norm (as defined for the respective test procedure). Note: Typically applies to non-numeric results. |
2.C.2.46 |
| AA | Critically abnormal | The result or observation value is outside a reference range or expected norm at a level at which immediate action should be considered for patient safety (as defined for the respective test procedure). [Note: Typically applies to non-numeric results. Analogous to critical/panic limits for numeric results.] | 2.C.2.46 | |
| null | No range defined, or normal ranges don't apply | Kein Referenzbereich / Referenzbereich nicht anwendbar | Deprecated | 2.C.2.46 |
| U | Significant change up | Deutlicher Trend nach oben | The current result has increased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure). | 2.C.2.46 |
| D | Significant change down | Deutlicher Trend nach unten | The current result has decreased from the previous result for a quantitative observation (the change is significant as defined in the respective test procedure). | 2.C.2.46 |
| B | Better | besser | The current result or observation value has improved compared to the previous result or observation value (the change is significant as defined in the respective test procedure). Note: This can be applied to quantitative or qualitative observations. |
2.C.2.46 |
| W | Worse | Verschlechterung | The current result or observation value has degraded compared to the previous result or observation value (the change is significant as defined in the respective test procedure). Note: This can be applied to quantitative or qualitative observations. |
2.C.2.46 |
| S | Susceptible | Bacterial strain inhibited by in vitro concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic success. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) Projects: ISO 20776-1, ISO 20776-2 Synonym (earlier term): Sensitive Note 1: Bacterial strains are categorized as susceptible by applying the appropriate breakpoints in a defined phenotypic system. Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms). | 2.C.2.46 | |
| R | Resistant | Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with a high likelihood of therapeutic failure. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) Projects: ISO 20776-1, ISO 20776-2 Note 1: Bacterial strains are categorized as resistant by applying the appropriate breakpoints in a defined phenotypic test system. Note 2: This breakpoint can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms). | 2.C.2.46 | |
| I | Intermediate | Bacterial strain inhibited in vitro by a concentration of an antimicrobial agent that is associated with uncertain therapeutic effect. Reference: CLSI (http://www.clsi.org/Content/NavigationMenu/Resources/HarmonizedTerminologyDatabase/Harmonized_Terminolo.htm) Projects: ISO 20776-1, ISO 20776-2 Note 1: Bacterial strains are categorized as intermediate by applying the appropriate breakpoints in a defined phenotypic test system. Note 2: This class of susceptibility implies that an infection due to the isolate can be appropriately treated in body sites where the drugs are physiologically concentrated or when a high dosage of drug can be used. Note 3: This class also indicates a “buffer zone,” to prevent small, uncontrolled, technical factors from causing major discrepancies in interpretations. Note 4: These breakpoints can be altered due to changes in circumstances (e.g., changes in commonly used drug dosages, emergence of new resistance mechanisms). | 2.C.2.46 | |
| MS | Moderately susceptible. Indicates for microbiology susceptibilities only. | mäßig empfindlich | Deprecated - CLSI now only supports S, I & R. This information can be found in CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012. |
2.C.2.46 |
| NS | Non-susceptible | A category used for isolates for which only a susceptible interpretive criterion has been designated because of the absence or rare occurrence of resistant strains. Isolates that have MICs above or zone diameters below the value indicated for the susceptible breakpoint should be reported as non-susceptible. Synonym: decreased susceptibility Note 1: An isolate that is interpreted as non-susceptible does not necessarily mean that the isolate has a resistance mechanism. It is possible that isolates with MICs above the susceptible breakpoint that lack resistance mechanisms may be encountered within the wild-type distribution subsequent to the time the susceptible-only breakpoint is set. Note 2: For strains yielding results in the “nonsusceptible” category, organism identification and antimicrobial susceptibility test results should be confirmed. | 2.C.2.46 | |
| SDD | Susceptible-dose dependent | A category that includes isolates with antimicrobial agent minimum inhibitory concentrations (MICs) that approach usually attainable blood and tissue levels and for which response rates may be lower than for susceptible isolates. Reference: CLSI document M44-A2 2009 “Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline – second edition” – page 2. | 2.C.2.46 | |
| IE | Insufficient evidence | There is insufficient evidence that the species in question is a good target for therapy with the drug. A categorical interpretation is not possible. Reference: EUCAST Note: A MIC with “IE” and/or a comment may be reported (without an accompanying S, I or R-categorization). | 2.C.2.46 | |
| SYN-R | Synergy - resistant | A category for isolates where the bacteria (e.g. enterococci) are not susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will not be effective. Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside. Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found. | 2.C.2.46 | |
| SYN-S | Synergy - susceptible | A category for isolates where the bacteria (e.g. enterococci) are susceptible in vitro to a combination therapy (e.g., high-level aminoglycoside and cell wall active agent). This is predictive that this combination therapy will be effective. Usage Note: Since the use of penicillin or ampicillin alone often results in treatment failure of serious enterococcal or other bacterial infections, combination therapy is usually indicated to enhance bactericidal activity. The synergy between a cell wall active agent (such as penicillin, ampicillin, or vancomycin) and an aminoglycoside (such as gentamicin, kanamycin or streptomycin) is best predicted by screening for high-level bacterial resistance to the aminoglycoside. Open Issue: The print name of the code is very general and the description is very specific to a pair of classes of agents, which may lead to confusion of these concepts in the future should other synergies be found. | 2.C.2.46 | |
| VS | Very susceptible. Indicates for microbiology susceptibilities only. | Sehr empfindlich | Deprecated - CLSI now only supports S, I & R. This information can be found in CLSI document M100-S22; Vol. 32 No.3; CLSI Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Jan 2012. |
2.C.2.46 |
| POS | Positive | A presence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure. | 2.C.2.46 | |
| NEG | Negative | An absence finding of the specified component / analyte, organism or clinical sign based on the established threshold of the performed test or procedure. Note: Negative does not necessarily imply the complete absence of the specified item. |
2.C.2.46 | |
| IND | Indeterminate | The specified component / analyte, organism or clinical sign could neither be declared positive / negative or detected / not detected by the performed test or procedure. | 2.C.2.46 | |
| DET | Detected | The measurement of the specified component / analyte, organism or clinical sign above the limit of detection of the performed test or procedure. | 2.C.2.46 | |
| ND | Not Detected | The presence of the specified component / analyte, organism or clinical sign could not be determined within the limit of detection of the performed test or procedure. | 2.C.2.46 | |
| AC | Anti-complementary substances present | Deprecated | 2.C.2.46 | |
| TOX | Cytotoxic substance present | Deprecated | 2.C.2.46 | |
| QCF | Quality Control Failure | Deprecated | 2.C.2.46 | |
| RR | Reactive | A presence finding used to indicate that the specified component / analyte reacted with the reagent above the reliably measurable limit of the performed test. | 2.C.2.46 | |
| WR | Weakly reactive | A weighted presence finding used to indicate that the specified component / analyte reacted with the reagent, but below the reliably measurable limit of the performed test. | 2.C.2.46 | |
| NR | Non-reactive | An absence finding used to indicate that the specified component / analyte did not react measurably with the reagent. | 2.C.2.46 | |
| OBX | Interpretation qualifiers in separate OBX segments | Deprecated | 2.C.2.46 | |
| HM | Hold for Medical Review | Deprecated | 2.C.2.46 |
| Links to Other/Further HL7 Information | generated: Aug 07, 2023 (FO) | |||
| Health Level Seven, Int. (HQ) |
HL7 Germany HL7 Europe |
Frank Oemig's HL7 Site (Infos about the database) |
HL7-Experts Network | |